Skip to main content
Premium Trial:

Request an Annual Quote

Lark Technologies Sets Date for Vote on Acquisition by Genaissance

NEW YORK, Feb. 20 (GenomeWeb News) - Lark Technologies will hold a vote of its stockholders to decide on the proposed acquisition by Genaissance Pharmaceuticals on April 1, the company said today.


New Haven, Conn.-based Genaissance announced its plan to acquire Lark, based in Houston, in December.

The all-stock transaction is valued at approximately $19.9 million, based on the closing price of Genaissance's common stock of $2.99 per share on Dec. 18, 2003.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.